Patient-reported outcome measures for use in clinical trials of SLE: a review

被引:33
|
作者
Izadi, Zara [1 ]
Gandrup, Julie [2 ]
Katz, Patricia P. [2 ]
Yazdany, Jinoos [2 ]
机构
[1] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA USA
来源
LUPUS SCIENCE & MEDICINE | 2018年 / 5卷 / 01期
关键词
QUALITY-OF-LIFE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CROSS-CULTURAL VALIDATION; B-LYMPHOCYTE STIMULATOR; FORM HEALTH SURVEY; IMPACT TRACKER; DISEASE-ACTIVITY; DOUBLE-BLIND; PSYCHOMETRIC PROPERTIES; RHEUMATOID-ARTHRITIS;
D O I
10.1136/lupus-2018-000279
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Inclusion of patient-reported outcomes is important in SLE clinical trials as they allow capture of the benefits of a proposed intervention in areas deemed pertinent by patients. We aimed to compare the measurement properties of health-related quality of life (HRQoL) measures used in adults with SLE and to evaluate their responsiveness to interventions in randomised controlled trials (RCTs). A systematic review was undertaken using full original papers in English identified from three databases: MEDLINE, EMBASE and PubMed. Studies describing the validation of HRQoL measures in English-speaking adult patients with SLE and SLE drug RCTs that used an HRQoL measure were retrieved. Twenty-five validation papers and 26 RCTs were included in the indepth review evaluating the measurement properties of 4 generic (Medical Outcomes Study Short-Form 36 (SF36), Patient Reported Outcomes Measurement Information System (PROMIS) item-bank, EuroQol-5D, and Functional Assessment of Chronic Illness Therapy-Fatigue) and 3 disease-specific (Lupus Quality of Life (LupusQoL), Lupus Patient Reported Outcomes, Lupus Impact Tracker (LIT)) instruments. All measures had good convergent and discriminant validity. PROMIS provided the strongest evidence for known-group validity and reliability among generic instruments; however, data on its responsiveness have not been published. Across measures, standardised response means were generally indicative of poor-moderate sensitivity to longitudinal change. In RCTs, clinically important improvements were reported in SF36 scores from baseline; however, between-arm differences were frequently non-significant and non-important. SF36, PROMIS, LupusQoL and LIT had the strongest evidence for acceptable measurement properties, but few measures aside from the SF36 have been incorporated into clinical trials. This review highlights the importance of incorporating a broader range of SLE-specific HRQoL measures in RCTs and warrants further research that focuses on longitudinal responsiveness of newer instruments.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Patient-reported outcome measures for use in clinical trials of SLE: a review (vol 5, e000279, 2018)
    Izadi, Z.
    Gandrup, J.
    Katz, P. P.
    LUPUS SCIENCE & MEDICINE, 2018, 5 (01):
  • [2] The Use of Patient-Reported Outcome Measures to Assess Clinical Features of Fibromyalgia in SLE
    Rogers, Jennifer
    Eudy, Amanda M.
    Criscione-Schreiber, Lisa
    Pisetsky, David
    Sun, Kai
    Doss, Jay
    Clowse, Megan E. B.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [3] CONTEMPORARY TRENDS IN USE OF PATIENT-REPORTED OUTCOME MEASURES OF HEALTH IN CLINICAL TRIALS
    Kuharic, M.
    Zecic, F.
    Pickard, A. S.
    VALUE IN HEALTH, 2020, 23 : S252 - S253
  • [4] The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials
    Coleman, Robert L.
    Beck, J. Thaddeus
    Baranda, Joaquina C.
    Jacobs, Ira
    Smoyer, Karen E.
    Lee, Lauren J.
    Askerova, Zemfira
    McGinnis, Justin
    Ganti, Apar Kishor
    ONCOLOGY, 2021, : 444 - 453
  • [5] Systematic review of the use of translated patient-reported outcome measures in cancer trials
    A. L. Slade
    A. Retzer
    K. Ahmed
    D. Kyte
    T. Keeley
    J. Armes
    J. M. Brown
    L. Calman
    A. Gavin
    A. W. Glaser
    D. M. Greenfield
    A. Lanceley
    R. M. Taylor
    G. Velikova
    G. Turner
    M. J. Calvert
    Trials, 22
  • [6] International guidance on the selection of patient-reported outcome measures in clinical trials: a review
    Norah L. Crossnohere
    Michael Brundage
    Melanie J. Calvert
    Madeleine King
    Bryce B. Reeve
    Elissa Thorner
    Albert W. Wu
    Claire Snyder
    Quality of Life Research, 2021, 30 : 21 - 40
  • [7] International guidance on the selection of patient-reported outcome measures in clinical trials: a review
    Crossnohere, Norah L.
    Brundage, Michael
    Calvert, Melanie J.
    King, Madeleine
    Reeve, Bryce B.
    Thorner, Elissa
    Wu, Albert W.
    Snyder, Claire
    QUALITY OF LIFE RESEARCH, 2021, 30 (01) : 21 - 40
  • [8] Utilization of patient-reported outcome measures in plastic surgery clinical trials: A review
    Foppiani, Jose
    Alvarez, Angelica Hernandez
    Stearns, Stephen A.
    Taritsa, Iulianna C.
    Weidman, Allan A.
    Valentine, Lauren
    Escobar-Domingo, Maria J.
    Foster, Lacey
    Schuster, Kirsten A.
    Ho, Olivia A.
    Rinker, Brian
    Lee, Bernard T.
    Lin, Samuel J.
    JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2024, 90 : 215 - 223
  • [9] Systematic review of the use of translated patient-reported outcome measures in cancer trials
    Slade, A. L.
    Retzer, A.
    Ahmed, K.
    Kyte, D.
    Keeley, T.
    Armes, J.
    Brown, J. M.
    Calman, L.
    Gavin, A.
    Glaser, A. W.
    Greenfield, D. M.
    Lanceley, A.
    Taylor, R. M.
    Velikova, G.
    Turner, G.
    Calvert, M. J.
    TRIALS, 2021, 22 (01)
  • [10] Patient-Reported Outcome Measures for Use in Clinical Trials and Clinical Practice in Inflammatory Bowel Diseases: A Systematic Review
    de Jong, Marin J.
    Huibregtse, Roxanne
    Masclee, Ad A. M.
    Jonkers, Daisy M. A. E.
    Pierik, Marie J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (05) : 648 - +